8-K: Oruka Secures $180M PIPE, ORKA-001 Shows Strong Phase 1 Data

Oruka Therapeutics announced a $180 million private placement and positive interim Phase 1 results for its lead asset, ORKA-001, targeting chronic skin diseases.

Summary

• Oruka Therapeutics secured approximately $180 million in gross proceeds through a private placement (PIPE) of common stock and pre-funded warrants.
• The PIPE involved the sale of 10,933,405 common shares at $15.00 per share and pre-funded warrants to purchase 1,066,666 shares at $14.999 per warrant.
• The company reported positive interim Phase 1 clinical trial results for ORKA-001, its long-acting IL-23p19 antibody for plaque psoriasis.
• ORKA-001 demonstrated an approximately 100-day half-life, which is over three times that of risankizumab, and achieved Cmax exposures exceeding risankizumab at an equivalent dose.
• Pharmacodynamic data showed complete and sustained inhibition of STAT3 signaling through 24 weeks.
• ORKA-001 was well tolerated across all dose levels (300 mg, 600 mg, 1200 mg) with a favorable safety profile consistent with the anti-IL-23 class.
• The company expects its cash, including the PIPE proceeds, to fund operations for at least one year beyond the ORKA-002 Phase 2 and ORKA-001 EVERLAST-B Phase 2b data readouts in 2027.
• Following the transaction, Oruka will have approximately 67.1 million shares of Common Stock and Common Stock equivalents issued and outstanding on a pro forma basis.

Sentiment

Score: 9

Explanation: The company successfully raised significant capital from reputable institutional investors, extending its cash runway well into 2027. Concurrently, it announced highly positive interim Phase 1 clinical data for its lead asset, ORKA-001, demonstrating a superior half-life and favorable safety profile compared to existing standards, which significantly de-risks the program and enhances its market potential. These two events combined represent a strong positive development for the company.

Positives

• Successful $180 million PIPE financing strengthens the company's financial position.
• ORKA-001 demonstrated an impressive half-life of approximately 100 days, significantly longer than risankizumab.
• Pharmacokinetic profile supports potential for once-yearly maintenance dosing and higher efficacy.
• ORKA-001 showed complete and sustained inhibition of STAT3 signaling through 24 weeks.
• Favorable safety profile consistent with the anti-IL-23 class, with no severe treatment-emergent adverse events or serious adverse events.
• Cash runway extended to at least one year beyond ORKA-002 Phase 2 and ORKA-001 EVERLAST-B Phase 2b data readouts in 2027.
• Strong institutional investor participation in the PIPE, including Viking Global Investors, Affinity Healthcare Fund, Blackstone, and Perceptive Advisors.

Negatives

• The PIPE financing involves significant dilution to existing shareholders, with 10,933,405 common shares and warrants for 1,066,666 shares being issued.
• Warrants have a beneficial ownership limitation of 9.99% (can be increased to 19.99% with 61 days notice), which could restrict immediate full exercise by large holders.

Risks

• Risks and uncertainties inherent in the drug development process, including the design and conduct of clinical trials.
• The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results do not necessarily predict final results.
• Risks related to the regulatory approval process and the timing of regulatory filings.
• Risks related to the company's ability to successfully establish, protect, and defend its intellectual property.
• Risks related to other matters that could affect the sufficiency of the company's capital resources to fund operations.
• Changes in the competitive landscape.
• Market conditions and the satisfaction of closing conditions for the PIPE financing.

Future Outlook

Oruka Therapeutics expects its cash, including the $180 million from the PIPE financing, to fund operations for at least one year following the ORKA-002 Phase 2 and ORKA-001 EVERLAST-B Phase 2b data readouts in 2027. The company anticipates initial data from the EVERLAST-A Phase 2a trial in 2H 2026 and plans to initiate the dose-ranging EVERLAST-B Phase 2b trial in 1H 2026. ORKA-001's pharmacokinetic profile supports the potential for once-yearly maintenance dosing, higher rates of skin clearance, and extended off-treatment remissions for plaque psoriasis patients.

Management Comments

• "ORKA-001s approximately 100-day half-life exceeded our expectations and has the potential to enable multiple upside scenarios for the program."
• "We are increasingly confident that ORKA-001 can redefine the standard of care in this important disease."
• "I'm very pleased with how quickly our team has progressed this program and by the enthusiasm we are hearing from investigators and patients."

Industry Context

The announcement positions Oruka Therapeutics as a strong contender in the chronic skin disease market, particularly for plaque psoriasis. The development of long-acting biologics with less frequent dosing is a key trend in the industry, aiming to improve patient adherence and quality of life. ORKA-001's significantly extended half-life compared to existing IL-23p19 inhibitors like risankizumab could provide a competitive advantage, potentially setting a new standard for treatment efficacy and convenience.

Comparison to Industry Standards

• ORKA-001's half-life of approximately 100 days is greater than three times that of risankizumab, a currently approved IL-23p19 inhibitor.
• ORKA-001 achieved a Cmax that exceeded risankizumab at an equivalent dose, based on previously reported risankizumab data.
• These pharmacokinetic properties suggest ORKA-001 could enable once-yearly maintenance dosing, a significant improvement over current therapies like risankizumab which are dosed four to six times per year.
• The achieved exposures are comparable to those in the KNOCKOUT study, which tested higher antibody exposures and could lead to best-in-class rates of skin clearance and extended off-treatment remissions.
• The safety profile of ORKA-001 is consistent with the anti-IL-23 class, indicating it is comparable to established therapies in terms of tolerability.

Stakeholder Impact

• Shareholders: Existing shareholders face dilution from the new share issuance but benefit from a significantly strengthened balance sheet and positive clinical data, which could drive future value.
• Investors (PIPE): New and existing institutional investors gain equity and warrants in a company with promising clinical assets and extended financial runway.
• Patients: The positive Phase 1 data for ORKA-001 suggests a potential for a new, highly effective, and more convenient treatment option (once-yearly dosing) for chronic skin diseases like plaque psoriasis.
• Employees: Enhanced financial stability and positive clinical progress can boost morale and provide job security, supporting ongoing research and development efforts.

Next Steps

• File a registration statement with the SEC for the resale of the common shares and pre-funded warrant shares by October 15, 2025.
• Use commercially reasonable efforts to have the registration statement declared effective within 90 days thereafter.
• Continue enrollment and dosing for the EVERLAST-A Phase 2a trial in moderate-to-severe plaque psoriasis patients.
• Present initial data from the EVERLAST-A Phase 2a trial in 2H 2026.
• Initiate the dose-ranging EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis patients in 1H 2026.
• Present clinical data from its Phase 1 trial of ORKA-001 and additional details on the EVERLAST-A trial design at the European Academy of Dermatology and Venerology Congress on September 18, 2025.

Key Dates

Recommendation

The combination of a substantial $180 million capital raise from leading institutional investors, significantly extending the company's cash runway into 2027, and highly positive interim Phase 1 clinical data for its lead asset, ORKA-001, presents a compelling investment case. ORKA-001's superior half-life and favorable safety profile compared to existing treatments suggest a potential best-in-class profile with the promise of once-yearly dosing, addressing a key unmet need in chronic skin diseases. This dual positive development substantially de-risks the company's financial position and its primary clinical program, indicating strong future growth potential and a likely positive market reaction.

Keywords

Oruka Therapeutics, ORKA, Private Placement, PIPE, ORKA-001, Plaque Psoriasis, IL-23p19 antibody, Clinical Trial, Phase 1 Results, Biotechnology, Drug Development, Chronic Skin Diseases, Warrants, Equity Financing, Nasdaq, Biologics, Dermatology, Pharmacokinetics, Pharmacodynamics, STAT3 inhibition, EVERLAST-A, EVERLAST-B